News for Agent

Daily business news: funding, M&A, launches

Funding

Evotec Secures $2.9 Million Gates Foundation Grant to Extend Stem Cell Safety Testing

By ·

Key takeaways

  • Evotec was awarded a $2.9 million grant by the Gates Foundation to extend a project begun in 2023 for a further three years.
  • Evotec's human stem cell-based platform screened more than 5,000 compounds across nine grantee programs during the initial collaboration.
  • Evotec previously received a $9.9 million Gates Foundation-led grant in April 2026 and a $2.5 million Gates Foundation-led grant in May 2025.

Evotec has been awarded a new $2.9 million grant by the Gates Foundation to support continued use of its human stem cell-based New Approach Methodologies for identifying potential safety risks to fetal development in novel drug candidates. Stock Titan reported the award on November 16, 2026.

How Evotec's Stem Cell Platform Works

The funding extends a project initiated in 2023 for a further three years, providing researchers working on global health programs with continued access to technology that can help assess potential risks earlier in drug discovery. Evotec's platform combines human induced pluripotent stem cell models with industrial-scale screening capabilities to model aspects of human development and to identify compounds that may pose developmental risks.

Over the course of the initial three-year collaboration, more than 5,000 compounds were screened across nine grantee programs. The development and validation of the platform are described in a recent bioRxiv preprint. Evotec's human stem cell-based platform forms part of its broader capabilities in New Approach Methodologies, which can potentially reduce reliance on animal testing and help improve research efficiency.

Dr. Joanna Holbrook, Chief Scientific Officer of Evotec, said: "Identifying potential safety risks early in the drug development process is essential to the efficient advancement of better medicines for global health priorities." Holbrook added that the platform allows researchers to investigate potential effects on prenatal development based on the behavior of human cells.

Evotec's Earlier Gates Foundation Grants

According to akta.pro company records, Evotec received a $9.9 million grant led by the Bill & Melinda Gates Foundation in April 2026 and a $2.5 million grant led by the Bill & Melinda Gates Foundation in May 2025. The same records list 19 funding rounds on file for the company.

Date Round Amount
2026-04 Grant $9.9 million
2025-05 Grant $2.5 million

Evotec's Path to the New Grant

In November 2026, Evotec signed a deal to sell its Toulouse biologics site to Sandoz for about $350 million upfront, including licensing, as part of a restructuring targeting 800 job cuts and approximately EUR 75 million in annual run-rate savings by end-2027, The future of trading reported. Evotec reported Q3 2026 group revenue of €164.9 million and nine-month revenue of €465.0 million, with adjusted EBITDA losses of €1.6 million and €44.3 million respectively, TradingView reported. Evotec kept its revenue goal of €1 billion by 2030 while adding €1 billion of potential upside from partner programs, FinanzNachrichten.de reported.

Companies in this story

Sources

Machine-readable: Markdown · JSON